Notas de prensa
- Industria biofarmacéutica
- General
Jesper Ericsson appointed new CEO of Symcel
Symcel Sverige AB today announces the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin, who is now retiring.
1 September 2017: Symcel has today announced that Jesper Ericsson has joined Symcel as Chief Executive Officer – with the appointment effective immediately. Ericsson was formally Director of Marketing and Sales at BioLamina AB, where he was responsible for direct sales both internationally and at a global and regional distributor level. During the past 10 years, Jesper has gained broad experience of the commercialization of research-based products through his work at the Unit for Bioentrepreneurship at the Karolinska Institute, Stockholm School of Entrepreneurship and as co-founder of the Stockholm BiotechBuilders Association. He holds a PhD in neuroscience from the Karolinska Institute and a MSc in medical technology from the Royal Institute of Technology in Stockholm.
Jesper Ericsson commented: ”I very much look forward to developing the plan and globally establishing Symcel's solutions for phenotypic screening - with a substantial focus on sales and marketing in the coming years”.
”Jesper’s experience in selling and marketing products towards the research market will strengthen Symcel's sales within different segments, especially for microbiology applications”, remarked Björn Varnestig, Chairman of Symcel.
“The Board wishes to thank Christer Wallin for his strong commitment and contribution over the past 6 years. During this time, the company's product CalScreener has been successfully developed and launched on the market. Christer has industrialized production processes and increased quality assurance”, Björn Varnestig added.
